The experimental hepatitis C treatment that BioCryst Pharmaceuticals (NASDAQ:BCRX) wants to take into clinical trials this year has run into an unexpected hitch: a patent for the compound was awarded to another pharmaceutical company. Biota was granted the patent in “an apparent error,” BioCryst said in a March 12 securities filing. The Feb. 21 patent […]
The investigational hepatitis C treatment under development by BioCryst Pharmaceuticals (NASDAQ:BCRX) is now ready to move into human studies following positive preclinical trial results released today. BioCryst expects to file an investigational new drug application on the compound BCX5191 in the fourth quarter. BioCryst believes BCX5191 can be developed into a drug with once-a-day dosing […]
Former Roche executive George Abercrombie has been elected to BioCryst Pharmaceuticals‘ (NASDAQ:BCRX) board of directors, his second appointment to the board of a North Carolina pharmaceutical company in the last month. In September, Abercrombie was named to the board of Tranzyme Pharma (NASDAQ:TZYM). Both companies are based in Durham, North Carolina. Abercrombie, who has more […]
